GSC
RANI icon

Ground Swell Capital’s Rani Therapeutics RANI Stock Holding History

Ground Swell Capital’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,153
Closed -$23.5K – 242
2024
Q4 		$23.5K Buy
+17,153
New +$36K 0.04% 116

Other funds holding RANI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ground Swell Capital's RANI Position: Q1 2025 in Review

Ground Swell Capital sold out of Rani Therapeutics (RANI) in Q1 2025, closing a stake of 17,153 shares — an estimated $23.5K sold.

Ground Swell Capital first reported a position in RANI in Q4 2024 and held it in 1 quarter. The position peaked at $23.5K in Q4 2024. 38 funds tracked by Wall St. Rank hold RANI as of Q1 2025.

  • Ground Swell Capital reported no remaining Rani Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ground Swell Capital sold 17,153 Rani Therapeutics shares in Q1 2025, an estimated $23.5K.
  • Ground Swell Capital first reported a position in Rani Therapeutics in Q4 2024 and held it in 1 quarter.
  • Ground Swell Capital's Rani Therapeutics position peaked at $23.5K in Q4 2024.
  • 38 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2025.

Based on Ground Swell Capital's 13F filing for Q1 2025, filed 13 May 2025.